944547-46-0
944547-46-0 性质
密度 | 1.53±0.1 g/cm3(Predicted) |
---|---|
储存条件 | Sealed in dry,Store in freezer, under -20°C |
溶解度 | 二甲基亚砜:≥100mg/mL(189.80mM) |
酸度系数(pKa) | 6.95±0.46(Predicted) |
形态 | 固体 |
颜色 | 浅黄至黄色 |
944547-46-0 用途与合成方法
Myc-MAX dimerization
Mycro 3 is a potent and selective c-Myc inhibitor in whole cell assays, with weak inhibitory activity against Activator protein 1 (AP-1). Mycro 3 has a superior specificity profile to its predecessors. Mycro 3 inhibits the interaction between c-Myc and Max. Mycro 3 has high selectivity and inhibits c-Myc/Max dimerization and conjugation with DNA. Mycro 3 exhibits an excellent specificity with IC 50 s of 0.25 and 9.0 µM for cells with intact Myc alleles and Myc-null cells, respectively.
Mycro 3 (100 mg/kg; oral administration; daily for two months) induces marked shrinkage of pancreatic ductal adenocarcinoma (PDA), increases cancer cell apoptosis, and reduces cell proliferation. Tumor growth is also drastically attenuated in Mycro 3-treated NOD/SCID mice carrying orthotopic or heterotopic xenografts of human pancreatic cancer cells.
Animal Model: | Moribund Pdx1-cre/KRAS * mice bearing pancreatic ductal adenocarcinoma (PDA) |
Dosage: | 100 mg/kg |
Administration: | Oral administration; daily for two months |
Result: |
Increased survival time.
Mycro 3 administration was discontinued after two months, the mouse survived for an additional month. |
944547-46-0 价格(试剂级)
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024-11-11 | XW94454746002 | 试剂Mycro-3 | 10mg | 352 | |
2024-11-08 | HY-100669 | 944547-46-0 | 944547-46-0 | 2mg | 1200 |